Prevalence, awareness and control of type 2 diabetes mellitus and risk factors in Chinese elderly population
CLINICAL APPLICATION OF GLP-1 IN LIPID METABOLISM AND ADIPOSE-RELATED DISORDERS Effects of glp-/glucose-dependent insulinotropic peptide dual agonists on lipid metabolism GLP-/glucose-dependent insulinotropic peptide (GIP) dual agonists are a new type of oral hypoglycemic drug, which can activate both GLP-1 and GIP incretin at the same time, thereby exerting a more comprehensive blood glucose control effect [125]
Lipase should not be interpreted without clinical context, liver tests cannot replace gallbladder imaging, and routine calcitonin screening has uncertain value
With so many options claiming to work, it's overwhelming to know which ones are built for this specific type of hair loss and which ones aren't
China Leads Market Growth with Rapid Treatment Adoption Revenue from obesity GLP-1 treatment in China is projected to exhibit strong growth with a CAGR of 25.4% through 2035, driven by rapidly increasing obesity rates in urban populations and growing consumer demand for weight management solutions
